TAS-205 showed no significant impact on motor function in patients with Duchenne muscular dystrophy (DMD), highlighting the ongoing search for effective treatments for the rare condition.

Capricor Therapeutics is expected to release data from the phase 3 HOPE-3 trial in Q3'25, thus presenting a potential path ...

A research team collected pain and prescription data from the medical records of 1,282 people with different types of ...

Medical research on muscular dystrophy and myopathy. Read about the promise of stem cell research for muscular dystrophy patients, and successful treatments tested in dogs.

Capricor Therapeutics (NASDAQ:CAPR) saw its stock plummet by 53% on Friday after the U.S. Food and Drug Administration issued a Complete Response Letter (CRL), rejecting the company’s bid for approval ...

The company said it was optimistic that the issues identified by the Food and Drug Administration could be resolved with new data.

Capricor’s BLA for Deramiocel was granted Priority Review in March 2025 and was supported by data from the HOPE-2 trial, its open-label extension (OLE), and natural history comparisons from FDA-funded ...

A Central Texas teen battling muscular dystrophy and complications that landed her in a Fort Worth hospital got a nice ...

PALO ALTO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced ...

Scientists have uncovered how a protein helps build and maintain vital brain connections, providing insights into the ...

The MESA data demonstrated sustained disease stabilization, reinforcing prior ARCH and CANYON findings. Importantly, CANYON participants w ...